UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment
UroGen Pharma表示,美国食品药品管理局接受潜在膀胱癌治疗的研究性新药申请
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册